Literature DB >> 16236922

Left atrial dysfunction in patients with atrial fibrillation after successful rhythm control for > 3 months.

Yi-Chih Wang1, Jiunn-Lee Lin, Juey-Jen Hwang, Mao-Shin Lin, Chuen-Den Tseng, Shoei K Stephen Huang, Ling-Ping Lai.   

Abstract

BACKGROUND: Large-scale clinical trials have demonstrated that patients with atrial fibrillation (AF), when treated with a rhythm-control strategy, are still at risk for embolic events. We hypothesized that left atrial (LA) dysfunction persisted even after successful maintenance of sinus rhythm for > 3 months.
METHODS: A total of 93 patients with AF and satisfactory rhythm control for > 3 months were included. Satisfactory rhythm control was defined as being free of AF based on patient-reported symptoms, monthly ECG follow-up, and ambulatory Holter ECG if needed. Among the 93 patients, 25 patients had sustained AF that was terminated by electrical or pharmacologic cardioversion, while 68 patients had paroxysmal AF under good medical control. Clinical data were obtained, and transthoracic and transesophageal echocardiography were performed after satisfactory rhythm control for > 3 months.
RESULTS: Among the 93 patients, 34 patients (37%) had LA dysfunction, defined as LA appendage (LAA) peak emptying velocity < 40 cm/s or spontaneous echo contrast and/or thrombus in the LA or LAA. When compared to the other 59 patients without LA dysfunction, they had larger LA dimension (40 +/- 6 mm vs 36 +/- 8 mm [+/- SD], p = 0.018) but did not differ significantly regarding the left ventricular (LV) chamber size, LV ejection fraction, mitral or tricuspid inflow, and ratio of the amplitude of the waves created by early diastolic filling and atrial contraction. We also analyzed the relationship between LA function and clinical risk factors for stroke, including hypertension, diabetes mellitus, coronary artery disease, age > 65 years, and prior cerebral vascular accident. LA dysfunction was found in 10 of 17 patients (59%) with three or more risk factors. The odds ratio for having LA dysfunction was 3.1 (p = 0.04; 95% confidence interval, 1.1 to 9.1) when compared with patients with less than three risk factors.
CONCLUSIONS: LA dysfunction was present in more than one third of AF patients after satisfactory rhythm control for > 3 months. Patients with higher burden (three or more) of clinical risk factors were more likely to have impaired LA function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16236922     DOI: 10.1378/chest.128.4.2551

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  [Persistent left atrial thrombus in atrial fibrillation under oral anticoagulation].

Authors:  B Leithäuser; F Kasch; T Broemel; J-W Park
Journal:  Herz       Date:  2010-12       Impact factor: 1.443

2.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

Review 3.  Left atrial appendage exclusion for atrial fibrillation.

Authors:  Faisal F Syed; Christopher V DeSimone; Paul A Friedman; Samuel J Asirvatham
Journal:  Cardiol Clin       Date:  2014-10-23       Impact factor: 2.213

Review 4.  Understanding the Pathobiology of Pulmonary Hypertension Due to Left Heart Disease.

Authors:  Jessica H Huston; Sanjiv J Shah
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

5.  Cardioembolic stroke in atrial fibrillation-rationale for preventive closure of the left atrial appendage.

Authors:  Boris Leithäuser; Jai-Wun Park
Journal:  Korean Circ J       Date:  2009-11-30       Impact factor: 3.243

6.  Unique evolution of Bivalvia arginine kinases.

Authors:  M Takeuchi; C Mizuta; K Uda; N Fujimoto; M Okamoto; T Suzuki
Journal:  Cell Mol Life Sci       Date:  2004-01       Impact factor: 9.261

Review 7.  Optimization Of Stroke Prophylaxis Strategies In Nonvalvular AF -Drugs, Devices Or Both?

Authors:  Amit Noheria; Faisal F Syed; Christopher V DeSimone; Samuel J Asirvatham
Journal:  J Atr Fibrillation       Date:  2015-08-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.